LACTNET Archives

Lactation Information and Discussion

LACTNET@COMMUNITY.LSOFT.COM

Options: Use Forum View

Use Monospaced Font
Show Text Part by Default
Show All Mail Headers

Message: [<< First] [< Prev] [Next >] [Last >>]
Topic: [<< First] [< Prev] [Next >] [Last >>]
Author: [<< First] [< Prev] [Next >] [Last >>]

Print Reply
Subject:
From:
cs translations <[log in to unmask]>
Reply To:
Lactation Information and Discussion <[log in to unmask]>
Date:
Tue, 10 Jun 2003 05:36:00 -0700
Content-Type:
text/plain
Parts/Attachments:
text/plain (116 lines)
Extreme caution with antidepressants and breastfeeding:

Breaking news re PAXIL (in US) or SEROXAT (in UK), a Fluorine/Fluoride
containing 
 anti-depressant, was just forwarded to us by Dawn Rider from Charles
Medawar. 
  

This is LONDON
09/06/03 - Business section

Glaxo faces storm over Seroxat
Alex Brummer, City Editor, Daily Mail

CLINICAL auditors from Britain's medicines control agency are expected to 
descend on Glaxo-SmithKline this week amid concerns that the pharmaceuticals 
group may have suppressed a series of negative studies on its key 
antidepressant drug Seroxat, known as Paxil in the US.

In a highly unusual move, a team from the Good Clinical Practice unit of the 
Medicines and Healthcare Products Regulatory Agency (MHRA) will demand 
access to all of GSK's files and studies on Seroxat.

The decision to take this dramatic step was taken following the delivery to 
the MHRA of nine studies of Seroxat that confirm the antidepressant can lead 
to suicidal tendencies and other medical damage when administered to people 
under the age of 18.

There has been extensive media coverage of the potential harmful effects on 
young people of Seroxat, one of GSK's leading compounds. But until now the 
company has declined to acknowledge any serious problems.

This week, however, it will be asked by the MHRA to contact general 
practitioners, letting them know of the potential dangers to people under 18.

Sources at GSK confirmed that an amendment to the instructions carried with 
Seroxat was under discussion with the authorities and an announcement would 
be made shortly. There was no knowledge of the impending clinical audit.

Disclosure of the regulatory concerns about Seroxat, which contributes 
£1.5bn-£2bn of annual turnover to GSK, is likely to lead to nervous selling 
on the stock market when it opens for business today. Glaxo shares have 
recovered to 1258p this year after falling below £10 in 2002.

Concerns that clinical practices may have slipped at Britain's flagship 
pharmaceuticals group will put additional pressure on the company's chief 
executive Jean-Pierre Garnier, who is already under fire over his possible 
£22m severance package.

A senior source at the MHRA told the Daily Mail that the decision to conduct 
an audit at GSK was 'very, very unusual'. 'Normally we have a good 
relationship with these guys and work closely together,' the source said.

If it were found that critical studies had not been available to regulators 
then GSK could eventually face criminal charges under the Medicines Act.

Previous Good Clinical Practice audits have been carried out at second-line 
pharmaceutical groups where research practices are sometimes less rigorous.

Members of the Committee on the Safety of Medicines, the licensing arm of 
the MHRA, were disturbed when they saw the parallel Seroxat and placebo 
studies recently submitted by GSK. They revealed a predilection to suicide, 
aggressive behaviour and other psychosis in Seroxat users under 18, which 
were not present in the placebo studies.

The belief is that a deep volume of research work showing 'contraindications 
in children' could not have been carried out overnight and the appropriate 
regulatory authorities should have been alerted much earlier - so 
appropriate amendments could be made.

The big worry for GSK now is that the disclosure of the disquiet at the MHRA 
and its offshoots could attract the attention of the Food & Drugs 
Administration in the US, which works closely with the British regulators.

That could seriously damage GSK's reputation in the US, where it does much 
of its business and where Garnier has his headquarters.

A spokesman for GSK said: 'We can confirm we are in discussion with the MHRA 
regarding proposed updates of the product characteristics of Seroxat. 
However, it is not appropriate to discuss this dialogue further until the 
outcome of this review.

'Seroxat is an important medication for treatment of anxiety and depression, 
and has been for more than 10 years. It has benefited the lives of millions 
of people suffering with these serious conditions.'
  
 A decision on the safety of Seroxat/Paxil, and other widely prescribed 
anti-depressants like Eli Lilly & Co's Prozac, will be announced tomorrow, 
according to the UK Medicines Control Agency. 'We will be making an 
announcement about Seroxat tomorrow but we're not saying anything in 
advance,' spokeswoman Alison Langley said.


Glaxo refused to comment on whether a clinical audit was being carried out, 
but confirmed it is in talks with the MHRA. 'We can confirm we are in 
discussion with the MHRA regarding proposed updates of the product 
characteristics of Seroxat,' Glaxo's Martin Sutton said.

. SEROXAT is one of the biggest selling antidepressants in the world. It 
treats depression, panic, obsessive compulsive disorder, post-traumatic 
stress disorder, social anxiety disorder and general anxiety disorder. Last 
year 400,000 people were prescribed the treatment, also known as the 
'anti-shyness pill', in Britain alone.

             ***********************************************

To temporarily stop your subscription: set lactnet nomail
To start it again: set lactnet mail (or digest)
To unsubscribe: unsubscribe lactnet
All commands go to [log in to unmask]

The LACTNET mailing list is powered by L-Soft's renowned
LISTSERV(R) list management software together with L-Soft's LSMTP(TM)
mailer for lightning fast mail delivery. For more information, go to:
http://www.lsoft.com/LISTSERV-powered.html

ATOM RSS1 RSS2